SUJALA TRADING & HOLDINGS LTD. Regd. Off. : lA, GRANT LANE, 2ND FLOOR.ROOM N0-202, KOLKAT A- 700 012 (West Bengal) Phone: (91-033) 2236-4330, E-mail:[email protected]/[email protected], CIN-L51109WB1981PLC034381 Website-www.sujalagroup.com Dated: 13-08-2021 To CRD- LISTING COMPLIANCE BSE LIMITED P.J. TOWER, DALAL STREET, MUMBAI- 400001 To THE LISTING DEPARTMENT THE CALCUTTA STOCK EXCHANGE LIMITED 7 LYONS RANGE, KOLKATA- 700001 Dear Sir, Script Id: 539117 I 29412 Sub: Outcome of the Board Meeting held on August 13, 2021 Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we report the outcome of the Board Meeting held today as follows: The statement of the Unaudited Standalone Financial Results for the Quarter ended 011 June 30, 2021 i? approved at the Board Meeting. A copy of the Unaudited Standalone Financial Result and Limited Review Report for the Quarter ended on June 30, 2021 are enclosed herewith. / The same is approved for the publication in the Newspaper. This is for your kind information and records. By Order of the Board . For Sujala Trading & Holdings Limiteli for SUJALA TRADING & HOLDiNGS_LTD .?<-? an.aging ·recto, Subhadeep Mukherjee Managing Director DIN: 03060827 •
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SUJALA TRADING & HOLDINGS LTD.Regd. Off. : lA, GRANT LANE, 2ND FLOOR.ROOM N0-202, KOLKAT A- 700 012 (West Bengal)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021
b 2. Deferred Ta.x
Total Expenses (Net)3 Profit/ (Loss) before exceptional items and tax
Exceptional Items
Profit I (Loss) before T,1x
Tax Expenses:
0.02
4J4
22.0.3
0.03
16.04
11.88
112.03
134.09
16.04
4.50
4.50
(24.29)
(24.29)
4.70 5.61
0.01 0.08
47.64 23.35
52.35 29.04
(24.29) 4?50I(24.29) 4.50
5.61
0.08
4.50
23.35
29.04
4.50
Rs. in Lac
Quarter Ended Year to date Year Ended
30.06.2021 30.06.2020 30.06.2021 31.03.2021
Unaudited Unaudited Unaudited Audited
33.54 27.97 33.54 150.04
0.09 0.09
33.54 28.06 33.54 150.13
IJ
Particulars
Total Revenue (Net)
Income
Revenue from Operationsb Other Income
Expenses
Cost of Material Consumed
b Purchase of stock-in-Trade
Chnange in Inventoriesof fiG, Stock-in-Trade and WIP
d Employee Benefit Expenses
Depriciation and Amortization Expensesf Finance Cost
g Other Expenses
Profit I (T.oss] for the perioo from continuing opt'rn.tions8 Profit I (Loss) for the period from discontinued operations9 Ta.x Expenses .;n discontinued operations
10 Profit I (Loss) from discontinued operations after tax
11 Profit I (Loss) for the period12 Other Comprehensive Income:
(1) Items that will not be classified to profit or loss
(2) Income T,._,: relating to items that will not be classified to profit or loss
Total comprehensive Income for the Period (comprising Profit / (Loss) and13 Other Comprehensive Income for the period)
SJ No
4.50 (24.29) 4.50 n.ss
572.18 572.18 572.18 572.18
0.08 (0.42) 0.08 0.21
0.081(0.42)10.0810.21 I
14 Paid -up Equity Shares Capital (Face Value ofRs.10/- per share)15 Earning per equity share (for continuing operation):
(1) Basic
(2) Diluted
16 Earning per equity share (for discontinued operation):
(1) Basic
(2) Diluted
17 Earning per equity share (for discontinued and continuing operation):
(1) Basic
(2) Diluted0.08
0.08
(0.42)
(0.42)
0.08
0.08
0.21
0.21Notes:
1 The above Financial Result were reviewedby the Audit Committee and taken on record & approved by the Board of Directors at their Meeting held on 13.08.2021
The Company has adopted IND AS as notified by the Ministry of Corporate Affairs and accordingly this Financial Results have been prepared in accordance with the2 Companies (Indian Accounting Standard) Rules, 2015 prescribed u/ s 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
3 The Company has only one segment, hence, no separate segemnt result were given.4 No Investor complaint was pending either at the beginning or received during the period under review: